Masimo Corporation (NASDAQ:MASI) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Masimo Corporation has received an average rating of "Moderate Buy" from six analysts, with one hold recommendation and five buy recommendations.
• Director William R. Jellison recently purchased 3,000 shares of Masimo stock, increasing his ownership by 167.6% and reflecting confidence in the company's prospects.
• The company reported $1.33 EPS for the last quarter, surpassing the consensus estimate of $1.22, with a year-over-year revenue increase of 7.7%.

Masimo Corporation (NASDAQ:MASI - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $193.60.

MASI has been the topic of several recent analyst reports. BTIG Research reaffirmed a "buy" rating on shares of Masimo in a research report on Monday, July 14th. Wells Fargo & Company dropped their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Raymond James Financial dropped their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen downgraded Masimo from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, Piper Sandler lifted their price objective on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th.

Insider Buying and Selling at Masimo

In other news, Director William R. Jellison acquired 3,000 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were bought at an average price of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director owned 4,790 shares of the company's stock, valued at $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.70% of the company's stock.

Institutional Trading of Masimo

Several institutional investors have recently bought and sold shares of MASI. Massachusetts Financial Services Co. MA increased its holdings in Masimo by 25.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,470,393 shares of the medical equipment provider's stock valued at $415,570,000 after purchasing an additional 502,555 shares during the last quarter. Capital Research Global Investors increased its holdings in Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after purchasing an additional 1,094,647 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in Masimo by 0.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,673,252 shares of the medical equipment provider's stock valued at $278,764,000 after purchasing an additional 10,876 shares during the last quarter. Westfield Capital Management Co. LP grew its stake in Masimo by 75.9% in the second quarter. Westfield Capital Management Co. LP now owns 1,181,203 shares of the medical equipment provider's stock valued at $198,702,000 after acquiring an additional 509,724 shares during the period. Finally, Durable Capital Partners LP acquired a new position in Masimo in the first quarter valued at about $187,528,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $155.96 on Thursday. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. The business's 50 day moving average is $161.70 and its two-hundred day moving average is $164.24. The company has a market cap of $8.47 billion, a P/E ratio of -18.31 and a beta of 1.21. Masimo has a 12 month low of $107.98 and a 12 month high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 EPS for the quarter, topping the consensus estimate of $1.22 by $0.11. The company had revenue of $370.90 million for the quarter, compared to the consensus estimate of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%. The company's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 EPS. On average, equities analysts expect that Masimo will post 4.1 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.